Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Gemtesa Generic Name & Formulations
Legal Class
Rx
General Description
Vibegron 75mg; tabs.
Pharmacological Class
Beta-3 adrenergic agonist.
How Supplied
Tabs—30, 90
Manufacturer
Generic Availability
NO
Mechanism of Action
Vibegron relaxes the detrusor smooth muscle during bladder filling by activation of the beta-3 adrenergic receptor which increases bladder capacity.
Gemtesa Indications
Indications
Overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Gemtesa Dosage and Administration
Adult
Swallow whole. Tabs may also be crushed, then mixed with a tablespoon of applesauce. 75mg once daily.
Children
Not established.
Gemtesa Contraindications
Not Applicable
Gemtesa Boxed Warnings
Not Applicable
Gemtesa Warnings/Precautions
Warnings/Precautions
Increased risk of urinary retention (esp. bladder outlet obstruction, patients taking antimuscarinic drugs for OAB); monitor and discontinue if develops. Severe hepatic impairment (Child-Pugh C) or renal impairment (eGFR <15mL/min/1.73m2): not recommended. Pregnancy. Nursing mothers.
Gemtesa Pharmacokinetics
Elimination
Fecal, renal. Half-life: 30.8 hours.
Gemtesa Interactions
Interactions
Potentiates digoxin; monitor serum digoxin levels prior to initiation, during, and after therapy (titrate and adjust dose as needed).
Gemtesa Adverse Reactions
Adverse Reactions
Headache, urinary tract infection, nasopharyngitis, diarrhea, nausea, upper respiratory tract infection; urinary retention.
Gemtesa Clinical Trials
See Literature
Gemtesa Note
Not Applicable
Gemtesa Patient Counseling
See Literature
Images
